Who We are, and what We can solve
This device solves an urgent clinical need for two different markets. It provides the under-served hemophilia patient population with the very first at-home, point-of care monitoring device and can also be immediately applied to the rapidly evolving $30B new class of oral anti-coagulants such as Pradaxa™, Xarelto™ or Eliquis™.
Patented platform technology can be made available to address all elements of blood and any conditions that might affect the patient condition – drug, disease or genetic in origin.
Unique handheld design that facilitates ease of use, while enabling multiple lines of product sales that include both hardware, consumables and data mining.
Already the recipient of industry accolades, having received honors at the 58th annual American Society of Hematology & Oncology (ASH) conference.
Seasoned management team has partnered with Nottingham Spirk to design and engineer the company’s products. Nationally recognized contract manufacturing, regulatory & quality management firms are supporting company growth.
Series A investment was successfully over-subscribed with a syndicate of experienced investors. The Company closed the anticipated $8m round at $9M. Use of proceeds are to support the completion of development of XaTek’s first commercial product, including a large multi-center pivotal trial and filing for FDA clearance in two different markets.